Gabapentin vs Oxycodone: Which Is Better for Pain?

Gabapentin and oxycodone treat pain through entirely different biological pathways, and they are rarely interchangeable in clinical practice. Gabapentin is an anticonvulsant that works best against nerve-related pain, while oxycodone is a potent opioid that targets a broader range of pain types but carries serious risks of dependence and overdose. The choice between them depends on what is causing your pain, how long you have had it, and what other medications you take, because combining the two brings its own dangers that have reshaped prescribing practices in recent years.

How They Work Differently

Gabapentin binds to a specific part of calcium channels on nerve cells, called the α2δ-1 subunit. That binding slows the movement of calcium channel components to the surface of pain-signaling neurons in the spinal cord, which dials down the release of excitatory chemical messengers involved in transmitting pain signals.¹ This makes gabapentin especially useful for pain that originates from damaged or misfiring nerves, such as diabetic neuropathy, shingles-related pain, or nerve compression injuries.

Oxycodone, by contrast, is a full opioid agonist. It activates mu-opioid receptors in the brain and spinal cord, broadly dampening pain perception and producing feelings of euphoria. That broad mechanism means oxycodone can treat a wider range of pain types, from surgical pain to cancer pain. But it also means oxycodone affects breathing, bowel function, and reward circuitry in ways gabapentin does not. The euphoria piece is what makes oxycodone so effective for acute severe pain and so risky for long-term use.

Head-to-Head in Acute Pain

Surprisingly few studies have pitted gabapentin directly against oxycodone for short-term pain after surgery or injury. In one trial comparing pre-emptive doses of gabapentin, oxycodone, and diclofenac before tibia fracture surgery, the three drugs performed similarly for most of the postoperative period. The only meaningful difference appeared at six hours after surgery, when pain scores in the gabapentin group were significantly lower than in the other two groups.² Total opioid use afterward and complication rates were similar across all three groups.

A separate trial in women undergoing abdominal hysterectomy found a more pronounced difference. Patients who received a single 1,200 mg dose of gabapentin before surgery reported significantly lower pain scores than those given oxycodone, used less rescue pain medication, and had less nausea and vomiting.³ These are individual trials with specific patient populations, so they do not settle the broader question. But they point to something clinicians increasingly recognize: for certain surgical settings, gabapentin given before the operation can work as well as or better than an opioid, with fewer gastrointestinal side effects.

Neuropathic and Chronic Pain

The clearest separation between these drugs shows up in chronic nerve pain. Gabapentin is a first-line treatment for conditions like diabetic neuropathy and postherpetic neuralgia, where the pain comes from nerve damage rather than tissue injury. For postherpetic neuralgia specifically, cost-effectiveness analyses have found gabapentin strongly favored over opioids as initial therapy, particularly in patients with heart disease.⁴ Opioids like oxycodone were not favored as first-line treatment in either population but were considered reasonable later in a treatment sequence if earlier options failed.

That said, some patients with neuropathic pain do not respond adequately to gabapentin alone. In a trial of patients with painful diabetic neuropathy already taking gabapentin, adding prolonged-release oxycodone cut pain scores by about a third from baseline. Pain relief was significantly better than continuing gabapentin with a placebo, and patients on the combination used less rescue medication and slept better.⁵ Tellingly, only 14% of patients on the combination dropped out for lack of effect, compared with 54% on gabapentin plus placebo. The combination clearly helped when gabapentin alone fell short, but it also introduced opioid-related risks the patient would not face with gabapentin alone.

Using Them Together to Reduce Opioid Doses

One of the most common real-world scenarios is not gabapentin versus oxycodone, but gabapentin added alongside oxycodone to reduce how much opioid a patient needs. This “opioid-sparing” approach is part of multimodal pain management, where several drugs with different mechanisms are layered together so no single agent has to be pushed to a high dose.

A systematic review of clinical evidence concluded that gabapentin reduces both pain intensity and opioid consumption after surgery compared with placebo, though head-to-head comparisons with other standard postoperative regimens were still lacking.⁶ In a more specific trial of patients undergoing weight-loss surgery, giving gabapentin before the operation reduced average oxycodone use in the first 12 hours by about 5 mg compared with placebo, a modest but statistically significant difference.⁷

Five milligrams may sound small, but in the context of opioid safety, every dose reduction matters. Lower opioid doses mean less risk of respiratory depression, less constipation, and potentially less exposure to the reward pathway that drives dependence. The opioid-sparing strategy is now a standard recommendation in most perioperative pain guidelines.

Side Effects Compared

The side-effect profiles of these two drugs overlap in some areas and diverge sharply in others. Both can cause drowsiness and dizziness. Beyond that shared territory, their problems look quite different.

Oxycodone’s signature side effects come from its opioid nature. Constipation is the most persistent complaint, and it does not tend to improve with time the way drowsiness does. In a trial of patients with acute shingles pain, over a quarter of those randomized to controlled-release oxycodone dropped out of the study, primarily because of constipation, compared with fewer than 7% in the placebo group.⁸ Nausea, itching, and respiratory depression at higher doses are also in the opioid package.

Gabapentin’s side effects lean more toward the neurological. Dizziness, sedation, and peripheral swelling (edema in the hands and feet) are the most common complaints. Weight gain can become an issue with long-term use. Gabapentin does not cause constipation to anywhere near the same degree, and it does not suppress breathing on its own.

When both drugs are used together for cancer pain, the combination tends to have less nausea, vomiting, and constipation than oxycodone-type opioids used alone, while rates of drowsiness and dizziness are similar between the combination and opioid-only approaches.⁹ The reason is straightforward: the combination lets clinicians use a lower opioid dose, so the dose-dependent opioid side effects ease up.

Addiction and Misuse Risk

Oxycodone is a Schedule II controlled substance in the United States, the same category as morphine and fentanyl. Its abuse potential is well documented and has been central to the opioid crisis. In a large cohort comparison with another opioid (tapentadol), oxycodone carried substantially higher odds of abuse diagnoses.¹⁰ Even reformulated “abuse-deterrent” versions of oxycodone have not eliminated the problem. A cohort study of abuse-deterrent extended-release oxycodone found rates of opioid use disorder and opioid poisoning that were actually higher than in cohorts prescribed non-abuse-deterrent opioids, likely reflecting prescriber selection, since patients perceived as higher-risk were more likely to receive the tamper-resistant formulation.¹¹

Gabapentin was long considered to have negligible abuse potential, but that view has shifted. A systematic review found clear evidence of tolerance, physical dependence, and withdrawal associated with gabapentin, warranting a serious reevaluation of its abuse potential.¹² The misuse pattern typically involves taking gabapentin at much higher doses than prescribed, often to amplify the effects of opioids or to produce a dissociative-like high. The drug is particularly sought after among people with existing opioid use disorders.¹³ Gabapentin remains unscheduled at the federal level, though several states have moved to classify it as a controlled substance and require prescriptions to be reported to monitoring databases.

The scales are not remotely even here. Oxycodone carries far greater inherent addiction risk. But the old framing of gabapentin as “completely safe from misuse” is outdated, and anyone taking it alongside opioids deserves to know that.

The Danger of Taking Both at Once

Here is where gabapentin and oxycodone interact in a way that has reshaped clinical caution. A large Canadian population-based study found that people prescribed both gabapentin and opioids had roughly 49% higher odds of opioid-related death compared with people taking opioids alone, even after adjusting for opioid dose and numerous other risk factors. At moderate and high gabapentin doses, the odds climbed to about 60% higher.¹⁴

A separate U.S. study analyzing over 24,000 opioid overdose cases found gabapentin co-prescription associated with increased overdose risk, including specifically among patients using only oxycodone.¹⁵ The mechanism is believed to involve additive central nervous system depression: both drugs increase sedation and, at sufficient doses, can suppress breathing. Gabapentin alone barely affects respiration, but in combination with an opioid, it amplifies the opioid’s respiratory depressant effects.

This does not mean the combination should never be used. As noted in the chronic pain section, adding oxycodone to gabapentin can help patients with severe diabetic neuropathy who are not getting enough relief otherwise. And the opioid-sparing strategy described earlier deliberately pairs the drugs to reduce total opioid exposure. The distinction matters: using a small dose of gabapentin to allow a lower dose of opioid is a very different risk equation from stacking high doses of both.

Fall Risk in Older Adults

For people over 65, both gabapentin and oxycodone individually raise concerns about dizziness, sedation, and falls. The combination adds a layer of risk that has been studied specifically. One study found that older adults using opioids and gabapentin concurrently had roughly 73% higher odds of experiencing a fall compared with those on opioids alone.¹⁶

A larger Medicare-based study added nuance to this picture. When older patients started gabapentinoids and opioids at the same time, the fall-injury risk was not significantly different from starting opioids alone. But when patients who were already on opioids then added a gabapentinoid, the risk of a fall-related injury increased by about 69%.¹⁷ The timing seems to matter: patients starting both simultaneously may adjust to the combined sedation gradually, while layering gabapentin onto an existing opioid regimen introduces a sudden change in central nervous system depression. For older adults, a fall can mean a broken hip, surgery, and a cascade of health problems, so the stakes of this interaction are not abstract.

Liver and Kidney Disease

The way your body processes each drug creates practical differences for people with organ impairment. Oxycodone is metabolized primarily by the liver through the cytochrome P450 enzyme system. In patients with significant liver dysfunction, oxycodone clearance drops and the drug lingers in the body longer, increasing the risk of overdose at normal doses.¹⁸ Dose reductions are usually necessary, and close monitoring is standard.

Gabapentin, by contrast, is not processed by the liver at all. It is excreted unchanged through the kidneys. This gives it an advantage in patients with liver cirrhosis, where it tends to be better tolerated than most analgesics.¹⁹ The flip side is that gabapentin accumulates in patients with poor kidney function, requiring dose reductions based on kidney filtration rates. Both drugs require precautions and dose adjustments in renal impairment, though the specifics differ.²⁰

In practical terms, if you have liver disease, gabapentin is the simpler choice from a safety standpoint. If you have kidney disease, both drugs need careful adjustment, but oxycodone’s metabolism is less directly affected by kidney function alone.

Prescribing Trends After the Opioid Guidelines

The 2016 CDC guideline on opioid prescribing for chronic pain reshaped how doctors in the United States approach both of these medications. While the guideline was not intended to discourage opioid use in cancer patients, it had spillover effects. Among older adults with cancer, gabapentinoid prescribing rates rose by roughly 25% in the period after the guideline was issued, while opioid prescribing patterns shifted as well.²¹ The increase in gabapentinoid use likely reflects clinicians reaching for non-opioid alternatives, or using gabapentinoids to reduce the opioid doses they prescribe.

This trend is not without its own concerns. The rising gabapentin prescription volume has contributed to the misuse and diversion patterns described earlier, and the combination safety data suggest that adding gabapentin to an existing opioid regimen requires the same level of caution that adding a second opioid would. The regulatory landscape is still catching up: while oxycodone prescribing is tightly monitored through prescription drug monitoring programs in every state, gabapentin monitoring varies widely. The assumption that gabapentin is a straightforward “safe alternative” to opioids oversimplifies a more complicated trade-off.

Pregnancy and Children

Neither gabapentin nor oxycodone is ideal during pregnancy, but they carry different types of risk. Limited safety data on gabapentin in pregnant women suggest it is unlikely to be a major cause of birth defects, though the evidence base remains thin. Short courses of weaker opioids are generally considered acceptable in pregnancy, but prolonged opioid use, particularly in the third trimester, raises the risk of neonatal abstinence syndrome, where the newborn experiences withdrawal symptoms after birth.

In children and adolescents, the evidence for gabapentin in surgical pain management is similarly sparse. A systematic review of opioid-sparing analgesics in pediatric surgical patients concluded that there was simply not enough data to draw conclusions about gabapentin’s perioperative use in this population.²² Opioids like oxycodone do have established pediatric dosing protocols for acute pain, but their use in children is carefully controlled given the respiratory depression risk. For both drugs, any use during pregnancy or in young patients involves weighing limited evidence against clear need, and that calculus should involve a specialist.

When Gabapentin Is the Obvious Choice, and When It Is Not

If you have chronic nerve pain, no history of kidney disease, and no acute injury demanding fast relief, gabapentin is the more natural starting point. It avoids the dependence risk of opioids, does not cause constipation, and has good evidence for conditions like diabetic neuropathy and postherpetic neuralgia. For patients with liver cirrhosis, gabapentin’s non-hepatic metabolism makes it a rare analgesic that does not add stress to an already compromised liver.

Oxycodone makes more sense for acute, severe pain that needs to be brought under control quickly, such as after major surgery, traumatic injuries, or in advanced cancer where pain intensity overwhelms what gabapentin can handle alone. Its broader mechanism of action and rapid onset give it tools gabapentin lacks in these situations. The trade-off is that every course of oxycodone carries a nonzero risk of beginning a dependence pattern, and its side-effect burden is heavier.

The most common clinical reality is not a clean either-or choice. Many patients end up on some version of both, with gabapentin reducing the opioid dose needed and oxycodone covering the pain that gabapentin cannot reach alone. Managed carefully, that combination can work well. Managed carelessly, especially in older adults or at escalating doses, it introduces respiratory and fall risks that neither drug carries to the same degree on its own.